536 related articles for article (PubMed ID: 34475132)
1. High-dose IL-2/CD25 fusion protein amplifies vaccine-induced CD4
Hernandez R; LaPorte KM; Hsiung S; Santos Savio A; Malek TR
J Immunother Cancer; 2021 Sep; 9(9):. PubMed ID: 34475132
[TBL] [Abstract][Full Text] [Related]
2. Sustained IL-2R signaling of limited duration by high-dose mIL-2/mCD25 fusion protein amplifies tumor-reactive CD8
Hernandez R; Toomer KH; Põder J; Santos Savio A; Hsiung S; Malek TR
Cancer Immunol Immunother; 2021 Apr; 70(4):909-921. PubMed ID: 33037893
[TBL] [Abstract][Full Text] [Related]
3. Robust IL-2-dependent antitumor immunotherapy requires targeting the high-affinity IL-2R on tumor-specific CD8
LaPorte KM; Hernandez R; Santos Savio A; Malek TR
J Immunother Cancer; 2023 Jun; 11(6):. PubMed ID: 37270181
[TBL] [Abstract][Full Text] [Related]
4. Immunological ignorance is an enabling feature of the oligo-clonal T cell response to melanoma neoantigens.
Linette GP; Becker-Hapak M; Skidmore ZL; Baroja ML; Xu C; Hundal J; Spencer DH; Fu W; Cummins C; Robnett M; Kaabinejadian S; Hildebrand WH; Magrini V; Demeter R; Krupnick AS; Griffith OL; Griffith M; Mardis ER; Carreno BM
Proc Natl Acad Sci U S A; 2019 Nov; 116(47):23662-23670. PubMed ID: 31685621
[TBL] [Abstract][Full Text] [Related]
5. Phase I Trial of Viral Vector-Based Personalized Vaccination Elicits Robust Neoantigen-Specific Antitumor T-Cell Responses.
D'Alise AM; Leoni G; Cotugno G; Siani L; Vitale R; Ruzza V; Garzia I; Antonucci L; Micarelli E; Venafra V; Gogov S; Capone A; Runswick S; Martin-Liberal J; Calvo E; Moreno V; Symeonides SN; Scarselli E; Bechter O
Clin Cancer Res; 2024 Jun; 30(11):2412-2423. PubMed ID: 38506710
[TBL] [Abstract][Full Text] [Related]
6. Mite-specific induction of interleukin-2 receptor on T lymphocytes from children with mite-sensitive asthma: modified immune response with immunotherapy.
Bonno M; Fujisawa T; Iguchi K; Uchida Y; Kamiya H; Komada Y; Sakurai M
J Allergy Clin Immunol; 1996 Feb; 97(2):680-8. PubMed ID: 8621854
[TBL] [Abstract][Full Text] [Related]
7. Aptamer-Targeted Attenuation of IL-2 Signaling in CD8
Rajagopalan A; Berezhnoy A; Schrand B; Puplampu-Dove Y; Gilboa E
Mol Ther; 2017 Jan; 25(1):54-61. PubMed ID: 28129128
[TBL] [Abstract][Full Text] [Related]
8. An effective mouse model for adoptive cancer immunotherapy targeting neoantigens.
Hanada KI; Yu Z; Chappell GR; Park AS; Restifo NP
JCI Insight; 2019 May; 4(10):. PubMed ID: 31092734
[TBL] [Abstract][Full Text] [Related]
9. Effective induction of therapeutic antitumor immunity by dendritic cells coexpressing interleukin-18 and tumor antigen.
Xia D; Zheng S; Zhang W; He L; Wang Q; Pan J; Zhang L; Wang J; Cao X
J Mol Med (Berl); 2003 Sep; 81(9):585-96. PubMed ID: 12937899
[TBL] [Abstract][Full Text] [Related]
10. High-throughput Screening of Human Tumor Antigen-specific CD4 T Cells, Including Neoantigen-reactive T Cells.
Costa-Nunes C; Cachot A; Bobisse S; Arnaud M; Genolet R; Baumgaertner P; Speiser DE; Sousa Alves PM; Sandoval F; Adotévi O; Reith W; Protti MP; Coukos G; Harari A; Romero P; Jandus C
Clin Cancer Res; 2019 Jul; 25(14):4320-4331. PubMed ID: 31015344
[TBL] [Abstract][Full Text] [Related]
11. CD4+/CD25+ regulatory cells inhibit activation of tumor-primed CD4+ T cells with IFN-gamma-dependent antiangiogenic activity, as well as long-lasting tumor immunity elicited by peptide vaccination.
Casares N; Arribillaga L; Sarobe P; Dotor J; Lopez-Diaz de Cerio A; Melero I; Prieto J; Borrás-Cuesta F; Lasarte JJ
J Immunol; 2003 Dec; 171(11):5931-9. PubMed ID: 14634104
[TBL] [Abstract][Full Text] [Related]
12. A Synthetic DNA, Multi-Neoantigen Vaccine Drives Predominately MHC Class I CD8
Duperret EK; Perales-Puchalt A; Stoltz R; G H H; Mandloi N; Barlow J; Chaudhuri A; Sardesai NY; Weiner DB
Cancer Immunol Res; 2019 Feb; 7(2):174-182. PubMed ID: 30679156
[TBL] [Abstract][Full Text] [Related]
13. ALKS 4230: a novel engineered IL-2 fusion protein with an improved cellular selectivity profile for cancer immunotherapy.
Lopes JE; Fisher JL; Flick HL; Wang C; Sun L; Ernstoff MS; Alvarez JC; Losey HC
J Immunother Cancer; 2020 Apr; 8(1):. PubMed ID: 32317293
[TBL] [Abstract][Full Text] [Related]
14. Multiple antigen-engineered DC vaccines with or without IFNα to promote antitumor immunity in melanoma.
Butterfield LH; Vujanovic L; Santos PM; Maurer DM; Gambotto A; Lohr J; Li C; Waldman J; Chandran U; Lin Y; Lin H; Tawbi HA; Tarhini AA; Kirkwood JM
J Immunother Cancer; 2019 Apr; 7(1):113. PubMed ID: 31014399
[TBL] [Abstract][Full Text] [Related]
15. Vaccination with an adenoviral vector encoding the tumor antigen directly linked to invariant chain induces potent CD4(+) T-cell-independent CD8(+) T-cell-mediated tumor control.
Sorensen MR; Holst PJ; Pircher H; Christensen JP; Thomsen AR
Eur J Immunol; 2009 Oct; 39(10):2725-36. PubMed ID: 19637230
[TBL] [Abstract][Full Text] [Related]
16. HCA587 Protein Vaccine Induces Specific Antitumor Immunity Mediated by CD4
Yang W; Zhang W; Wang X; Tan L; Li H; Wu J; Wu Q; Sun W; Chen J; Yin Y
Anticancer Agents Med Chem; 2021; 21(6):738-746. PubMed ID: 32723258
[TBL] [Abstract][Full Text] [Related]
17. Targeting of the non-mutated tumor antigen HER2/neu to mature dendritic cells induces an integrated immune response that protects against breast cancer in mice.
Wang B; Zaidi N; He LZ; Zhang L; Kuroiwa JM; Keler T; Steinman RM
Breast Cancer Res; 2012 Mar; 14(2):R39. PubMed ID: 22397502
[TBL] [Abstract][Full Text] [Related]
18. Depletion of CD25(+) CD4(+) T cells and treatment with tyrosinase-related protein 2-transduced dendritic cells enhance the interferon alpha-induced, CD8(+) T-cell-dependent immune defense of B16 melanoma.
Steitz J; Brück J; Lenz J; Knop J; Tüting T
Cancer Res; 2001 Dec; 61(24):8643-6. PubMed ID: 11751377
[TBL] [Abstract][Full Text] [Related]
19. A liposomal RNA vaccine inducing neoantigen-specific CD4
Salomon N; Vascotto F; Selmi A; Vormehr M; Quinkhardt J; Bukur T; Schrörs B; Löewer M; Diken M; Türeci Ö; Sahin U; Kreiter S
Oncoimmunology; 2020 Jun; 9(1):1771925. PubMed ID: 32923128
[TBL] [Abstract][Full Text] [Related]
20. Dendritic cells loaded with stressed tumor cells elicit long-lasting protective tumor immunity in mice depleted of CD4+CD25+ regulatory T cells.
Prasad SJ; Farrand KJ; Matthews SA; Chang JH; McHugh RS; Ronchese F
J Immunol; 2005 Jan; 174(1):90-8. PubMed ID: 15611231
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
